



ADAP Advocacy Association
PO Box 15275
Washington, DC 20003

adapadvocacyassociation.org

Board of Directors:

Co-Chair

William E. Arnold
Washington, D.C.

Co-Chair

Philip A. Haddad, M.D.
Shreveport, LA

Secretary/Treasurer

Michelle Anderson
Dallas, TX

Elmer Cerano
Lansing, MI

Glen Pietrandoni R.Ph.
Deerfield, IL

Eric Flowers
Oakland, CA

Darryl Fore
Cleveland, OH

Joey Wynn
Fort Lauderdale, FL

Robert Suttle
New York, NY

Wanda Brendle-Moss
Winston-Salem, NC

Janine Brignola
Omaha, NE

Chrys Thorsen
Los Angeles, CA

CEO
Brandon M. Macsata
Washington, D.C.

Directors Emeritus:

Rani Whitfield, MD
Gary Rose
John D. Kemp, Esq.
Joyce Turner Keller

ADAP Advocacy Association Launches 340B Service Caucus

“New Caucus Brings Patient Perspective to the Debate Over 340B Drug Pricing Program”

For Immediate Release:
January 28, 2016

Media Contact:
Brandon M. Macsata
(305) 519-4256

WASHINGTON, D.C. (January 28, 2016) – The [ADAP Advocacy Association](http://www.adapadvocacyassociation.org), also known as **aaa+**[®], today launched its new 340B Service Caucus. The Caucus comes in response to the ongoing debate over the 340B Drug Pricing Program, which requires drug manufacturers to provide outpatient drugs to eligible health care organizations/covered entities at significantly reduced prices.

“The 340b Service Caucus – in collaboration with our corporate partners, strategic alliances, and nonaffiliated supporters – provides a neutral platform for stakeholders to discuss the 340B drug pricing program and related public policy initiatives, as well as the Continuum of Care for patients living with HIV/AIDS whom directly and indirectly received their care from Ryan White covered entities, ADAPs, and affiliated clinical providers,” said **Brandon M. Macsata**, CEO of the ADAP Advocacy Association. “It will also promote education and trainings from the *patient* perspective.”

The 340B Drug Pricing Program provides much more than better pricing to the eligible Ryan White entities; it provides an opportunity for these nonprofit agencies to generate revenue that is reinvested back into the HIV/AIDS community in the form of expanded care and treatment capacity. This benefit extends to ADAPs, AIDS Service Organizations, community clinics, and their patients. As the Affordable Care Act (ACA) and Ryan White program continue to intersect, especially in states where Medicaid expansion has not and *is not* likely to occur anytime in the near future, programs such as the 340B program will continue to play an important role in the service delivery system.

To learn more about the 340B Drug Pricing Program, go to www.hrsa.gov/opa/.

To learn more about the ADAP Advocacy Association or its 340B Services Caucus, please email info@adapadvocacyassociation.org.

####